Genmab — Juli 2020

[StockBull]

https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/85254_ta_koere_planmaessigt.PNG kurstarget 2400

[Solsen]

Hvad gætter du at på udfaldet bliver, når Genmab forlader kanalen ?

[Helge_LarsenPI-redaktør]

Pharma har vendt rundt til negativt terræn efter en flot start på dagen.

[E_L]

@Solsen then the rising Wedge will just turn into a rising Channel, with an upper trendline already at around 2700 . easy.

[Solsen]

I take that

[Helge_LarsenPI-redaktør]

Me too.

[Solsen]

And yes Helge - someone besides me have to think its time for taking profit.

[E_L]

and i forgot earlier, i expect we hear something by August about what Genmab wants to do with Cami-t https://twitter.com/adctherapeutics/status/1285589645275865088

[gdn55]

Husk stilhed før stormen.

[StockBull]

Tror bare Genmab følger den positive trend fra USA og samme når det vender. RSI er ved at nærme sig det niveau hvor der normalt kommer en retracement hvor vi skal 10% ned eller deromkring

[bikube]

Det er godt nok voldsomt, så hurtigt $ kursen falder. Det er ikke let at budgettere med.

[DevOp]

Og vi kan nok godt risikere, at det fortsætter nedad med dollarkursen https://edition.cnn.com/2020/07/16/investing/us-dollar-coronavirus-trump/index.html

[Helge_LarsenPI-redaktør]

God morgen.

[bibob]

God morgen.

[bibob]

FDA approval sought for Selinexor in Myeloma after 1 prior line of therapy. https://www.onclive.com/view/fda-approval-sought-for-selinexor-in-myeloma-after-1-prior-line-of-therapy?eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

[Stroka]

Genmab i rekord får lagt 18,5 pct. til kursmålet hos Bernstein

06:40
Det amerikanske finanshus Bernstein har løftet sit kursmål for Genmab med 18,5 pct. til 2275 kr. fra 1920 kr.

Samtidig holdes der fast i den positive anbefaling outperform, fremgår det af data fra Bloomberg News.

Genmab-aktien er - ligesom store dele af det danske marked - inde i en god periode lige nu, og tirsdag sluttede aktien atter i rekord, da den steg med 0,1 pct. til 2340 kr.

[E_L]

Transcript of Novartis earnings call https://finance.yahoo.com/news/edited-transcript-novn-earnings-conference-214116224.html When you look at our late-stage pipeline, just to go through some of the key assets in detail, ofatumumab, we continue to have very good discussions with FDA. We're on track for our action date in September of 2020, no major issues. And happy to, of course, answer any questions, but we feel very good about where we are in that discussion and the ongoing label negotiation.

[E_L]

a few more comments on Ofa there, but maybe a bit too much to paste all here

[Helge_LarsenPI-redaktør]

It´s ok to do it.

[Helge_LarsenPI-redaktør]

Then we will have the information in the chat-history.